Arcutis Biotherapeutics, Inc. (ARQT) Tops Q3 EPS by 18c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q3 EPS of ($0.73), $0.18 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $38.1 million versus the consensus estimate of $32.83 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Morgan Stanley Downgrades Melco Resorts (MLCO) to Equalweight
• Goldman Sachs Starts Chagee Holdings (CHA) at Neutral